Format

Send to

Choose Destination
Trends Pharmacol Sci. 2005 Nov;26(11):541-4. Epub 2005 Sep 16.

The connections between C75 and obesity drug-target pathways.

Author information

1
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. fkuhajda@jhmi.edu

Abstract

Obesity and its attendant disorders, such as Type II diabetes, have reached epidemic proportions in the USA, and their prevalence is increasing globally. C75 is a small-molecule inhibitor of fatty acid synthase (FAS) and a stimulator of carnitine palmitoyl 1 activity, which causes profound weight loss in mice. Although C75 is not a compound that is destined for human drug development, it has provided two potential pathways to target in obesity therapy: fatty acid synthesis and fatty acid oxidation. In this article, we discuss the latest data challenging the relationship between fatty acid synthase inhibition and C75-induced anorexia.

PMID:
16169094
DOI:
10.1016/j.tips.2005.09.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center